Gendai Echezona, MD
Pain Medicine · Norwalk, CTNPI 1871737718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boston Scientific at 41.9% of the total. Reporting peaked in 2023 at $573 and has fallen 67.6% since, to $186 in 2025.
Across 41 payments — averaging $55.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$958
- Medtronic$645
- Galderma Laboratories, L.p.$210
- Merz North America, Inc.$200
- GRT US Holding, Inc.$136
- SPR Therapeutics, Inc$66
- plus $70 from 2 others
What the payments were for
- Food & beverage$2,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $958 |
| Medtronic(2 entities) | 9 | $645 |
| Galderma Laboratories, L.p. | 2 | $210 |
| Merz North America, Inc. | 1 | $200 |
| GRT US Holding, Inc. | 2 | $136 |
| SPR Therapeutics, Inc | 1 | $66 |
| Abbott | 2 | $45 |
| Nevro Corp. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$270
- XEOMIN$200
- VANTA ADAPTIVESTIM$151
- GENERAL PAIN MANAGEMENT$121
- General$120
- Qutenza$115
How this compares
$2,284 in reported general payments places this provider in the 55th percentile of 69 pain medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 30 | $2,104 |
| Gabapentin | 92 | $1,585 |
| Duloxetine Hcl | 25 | $549 |
| Diclofenac Sodium | 17 | $352 |
| Pregabalin | 31 | $338 |
| Methocarbamol | 22 | $174 |
| Methylprednisolone | 16 | $131 |
| Meloxicam | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Norwalk
- Caroline VarlottaNorwalk$1K
- Daniel SouthernNorwalk$221
- Michael SmithNorwalk$158
- Sandeep JoharWaterbury$329K
- David GutierrezNew Haven$151K
- Brian GrosbergWest Hartford$99K
- Ofer WellischStamford$18K
- Yili HuangNew Haven$18K
- Jared RosenbergGreenwich$12K
- Sandhya MehlaWest Hartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.